Most researchers treat the decline we see in our sixties as a mechanical breakdown, but we should probably see it as a negotiated settlement. Longevity science relies on a quiet assumption: that every human genome is hardwired for 120 years of life, and anything less is just a bug we need to patch. Evolution isn't that generous. We aren't a uniform pack of long-lived survivors. Instead, we’re a collection of distinct metabolic contracts, each tuned for specific environmental pressures.

When we look at aging through the lens of life-history trade-offs, the question shifts. We shouldn't ask why "short-lived" individuals fail; we should ask what their bodies were actually optimized for. Things like high inflammatory profiles or aggressive nutrient sensing are usually labeled as "pro-aging" errors. They aren't. They’re high-performance signatures meant for a world where surviving a childhood infection or winning a fight at twenty mattered more than a heart attack at fifty. It's a trade-off that worked.

Current funding models and clinical trials are obsessed with finding a universal fix—a single pill for everyone. But if a 65-year-old’s aging process is just the final chapter of a high-burn biological script, "reversing" it with a standard senolytic doesn't make sense. It’s like trying to turn a sprinter into a marathon runner halfway through the race. You won't get a better athlete; you'll just trigger a metabolic identity crisis.

We have to start talking about Lineage-Specific Longevity. Right now, we aren't stratifying cohorts based on their evolutionary "bets." Some people are simply incentivized to exit earlier; their biological scaffolds are built to erode faster to keep their early-life plasticity high. Ignoring this means we're treating the vast diversity of human biology as a spreadsheet error.

It's time to admit that the "one size fits all" approach is essentially scientific erasure. We need to stop viewing polymorphic aging rates as noise and start seeing them as the signal. If we don't acknowledge these different biological contracts, we aren't really extending life. We're just trying to force a short-haul genome to fly a long-haul route. And nobody’s asking what that actually costs the body.